The United States and United Kingdom Establish Tariff-Free Pact on Pharmaceuticals.

The UK and US have hammered out a major commercial pact that will preserve no duties on British pharmaceutical shipments going into the American market.

The Terms of the Deal

As part of the deal, the UK has pledged to boost expenditure on drugs through the National Health Service (NHS). This move ensures that import taxes on these key exports will remain at zero for a timeframe of the next three years.

This agreement is in response to earlier statements to dramatically increase import taxes on patented pharmaceutical products, with figures mentioned up to 100%.

"This arrangement between the United Kingdom reinforces the international landscape for new treatments and establishes long-overdue balance to U.S.–U.K. drug exports," a release said.

Commercial Importance

Drugs constitute one of the Britain's most significant export categories to the United States, which is clearly the biggest buyer for large companies like GSK and AstraZeneca.

Statistics show that in the year prior to the third quarter, the UK shipped pharmaceutical products totaling billions to the US. This amount represented 17.4% of British export trade in that period.

"This guarantee safeguards jobs, stimulates capital expenditure and sets the stage for the UK to become a worldwide center for life sciences," a minister stated.

Key UK Commitments

The deal entails several specific changes from the United Kingdom:

• Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
• Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
• Payback Limit: The amount pharmaceutical firms must return to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates were more than twenty percent.

Recent Tensions

The deal takes place against a ongoing tension between the drug companies and the UK government over medicine costs and regulatory access.

The disagreement were intensified by claims that US consumers were charged significantly more for the equivalent treatments than consumers in the UK and Europe.

Recently, several significant manufacturing plans in the UK have been delayed or cancelled, while major funding commitments have been announced toward US facilities.

One official publicly accepted that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the past decade.